Most material SEC filings — September 30, 2026

On September 25, 2026, Marygold Companies entered into a definitive merger agreement with funds managed by Madison Dearborn Partners to acquire all outstanding shares at $2.00 per share. The Board's Special Committee and full Board unanimously approved the transaction, and holders of approximately 75% of voting shares delivered written consent approving the Merger Agreement. The Company conducted an extensive process prior to the deal and received several alternative proposals.

Peoples Bancorp Inc. (Ohio, ~$1.0B market cap) agreed to acquire Capital Bancorp Inc. (Maryland) in an all-stock merger effective September 29, 2026. Capital shareholders receive 1.11 Peoples Common Stock per share (the Exchange Ratio). The merger requires shareholder approval from both companies and regulatory approval from FRB, OCC, FDIC, ODFI, MDOFR, and others. Closing expected in first business day of month following final regulatory approval.

Cal-Maine Foods reported Q1 FY2027 (ended August 29, 2026) net sales of $539.6M vs. $922.6M prior year (−41.5%), with net loss of $58.6M vs. net income of $199.3M (−$257.9M swing). Conventional Shell Eggs segment revenue fell 59.5% due to 59.3% price decline from industry oversupply post-flock repopulation; segment loss was $71.0M vs. $168.2M income prior year. Specialty Shell Eggs and Prepared Foods now represent 54.1% of sales (up from 37.1%). Company acquired Eggland's Best franchise in Northeast and continues capacity expansion targeting 60%+ growth in Prepared Foods by H1 FY2028. Repurchased 66,601 shares for $5.0M in Q1; suspended dividend until cumulative loss of $94.5M is recovered.

Zedge completed a $7.7M private placement generating gross proceeds of $7.675M. Vice Chairman Howard Jonas (via Chartwell Holding LLC) invested $6.5M for 2,218,430 shares of Class B common stock and warrants to purchase 1,996,587 shares at $3.22/share exercise price. Board member Elliott Gibber and another shareholder also participated. Total issuance: 2,616,447 shares and warrants for 2,354,803 shares. Proceeds will fund DataSeeds.AI expansion.

Peoples Bancorp Inc. (Ohio) agreed to acquire Capital Bancorp Inc. (Maryland) in an all-stock merger dated September 29, 2026. Capital shareholders will receive 1.11 shares of Peoples Common Stock per Capital share (Exchange Ratio). Capital Bank will merge into Peoples Bank. No specific dollar amount or stock counts provided in the filing excerpt; Capital Bancorp's market value is ~$374.6M. Deal is structured as a tax-free reorganization under IRC Section 368(a)(1)(A).

Connect reported topline results from the Phase 2 Seabreeze STAT COPD trial (159 participants, 1:1 randomization) showing rademikibart 600 mg subcutaneous significantly reduced treatment failure by 81% (p=0.0122), new moderate-to-severe exacerbations by 85% (p=0.030), and hospital/ED returns by 100% (p=0.0137) through Week 4. The drug showed a favorable safety profile comparable to placebo. Company plans FDA engagement for Phase 3 development in acute and chronic COPD indications.

Professional Diversity Network, Inc. (NASDAQ: IPDN) received written confirmation on September 28, 2026 from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share. The company had been notified on June 5, 2026 that its stock had closed below $1.00 for 30 consecutive business days. Following a reverse stock split, the closing bid price remained at or above $1.00 from September 14–25, 2026, resolving the compliance matter.

Rafael Holdings announced September 30, 2026 topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in 94 Niemann-Pick Disease Type C patients (63 drug, 31 placebo). The primary endpoint—change in 4DNPCSS at Week 96—did not achieve statistical significance (p=0.19), showing 64% slowing of disease progression. However, a prespecified subgroup analysis of 78 patients (83% of study population) on background miglustat and/or leucine therapy showed statistical significance (p=0.046) with 71% disease progression slowing. Company remains on track for NDA submission in Q4 2026 pending FDA review.

AEON received FDA feedback on ABP-450 (botulinum toxin biosimilar to BOTOX) development. The FDA agreed in principle to a two-stage comparative pharmacodynamic (CMAP) study design and indicated previously completed Daewoong studies in blepharospasm, upper limb spasticity, and cosmetic indications may be submitted as supportive evidence with scientific bridging. AEON plans to submit an IND for the CMAP study in Q4 2026 and intends to avoid a standalone comparative efficacy study by leveraging analytical, pharmacodynamic, and existing comparative human evidence; the company expects to return to the FDA in 2027 with an integrated evidence package.

Celcuity announced on September 30, 2026, that REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without PIK3CA mutation following progression after endocrine therapy. FDA approved the drug on July 14, 2026, for use in combination with fulvestrant alone (doublet) or with palbociclib plus fulvestrant (triplet). In the Phase 3 VIKTORIA-1 trial's PIK3CA wild-type cohort, REVTORPYK triplet and doublet reduced risk of disease progression or death by 76% and 67% respectively versus fulvestrant. The company has launched REVTORPYK Support Services for patient access and reimbursement assistance.

ACM Research's Shanghai subsidiary reported total backlog of RMB 17.1 billion (~$2.5 billion USD) as of September 29, 2026, representing an 88.2% year-over-year increase. The backlog includes both shipped tools not yet revenue-recognized under Chinese GAAP and future-shipment orders. Full financial results for Q3 2026 will be reported in early November 2026.

DarkIris Inc., a Cayman Islands gaming/AIGC company with ~$8.4M in assets, filed an F-1 registration statement on September 30, 2026 for a best-efforts public offering of up to 4.17M Units ($1.20/unit) + 4.17M Pre-Funded Units ($1.1999/unit), plus Warrants. Assumed gross proceeds ~$5M; net proceeds after 5% placement fee and expenses ~$4.59M. No minimum raising threshold; best-efforts means company may raise substantially less. As adjusted, post-offering capitalization ~$14.1M; existing shareholders face ~96% dilution if all Warrants exercised at zero exercise price (highly likely per prospectus). CEO Hong Zhifang controls 97.48% voting power pre-offering; post-offering ~52.55% if all shares issued.

Sagimet announced positive 52-week results from Ascletis' Phase 3 open-label extension trial (ASC40-304) of denifanstat in moderate-to-severe acne in China: 240 patients (116 continuous denifanstat, 124 placebo-to-denifanstat) achieved 56.7% treatment success rate, 71.8% reduction in total lesion count, and 76.9% reduction in inflammatory lesion count. Drug was well-tolerated (dry skin 7.1%, dry eye 5.9%). Sagimet plans to initiate its US Phase 3 AURORA trial (~800 patients, 450 adolescents aged 12-17) in 2H 2026 with patient screening expected in October 2026. Company has $257.6M cash (as of 6/30/2026, including $175M from April 2026 equity offering) expected to fund operations through 2028 and denifanstat Phase 3 readout.

The Hartford's Board named President A. Morris Tooker as CEO effective March 1, 2027, succeeding Christopher Swift, who will transition to executive chair (stepping down in H2 2027). Tooker, who joined Hartford in 2015 as chief underwriting officer and has held successive leadership roles, will join the board effective October 1, 2026. Swift led the company for nearly 13 years as CEO, overseeing a transformation that more than tripled net income ROE and drove an eightfold increase in share price.

Jabil (JBL, $14.4B market cap) reported FY2026 net revenue of $36.0B (up 21% YoY from $29.8B), core operating income of $2.1B, core diluted EPS of $13.09, and adjusted free cash flow of $1.53B. FY2027 guidance: revenue $44.5B (24% growth), core operating margin 6.1% (30 bps expansion), core diluted EPS $17.55 (34% growth), adjusted FCF ~$1.6B. Q4 FY2026 revenue was $10.6B with core operating income of $675M and core diluted EPS of $4.40. Growth driven by AI infrastructure demand and diversified end markets (automotive, healthcare, energy, defense, aerospace, automation).

General Mills announced that Dana McNabb, current Chief Operating Officer with 27 years at the company, will succeed Jeff Harmening as CEO effective January 1, 2027. Harmening transitions to Executive Chair. McNabb has led all four operating segments and key functions including North America Retail, North America Pet, Foodservice, and International; Harmening's tenure delivered $17B to shareholders via dividends and buybacks while revamping portfolio and expanding into Pet category.